Tyrosine kinase inhibitorFDA-approvedFirst-line
Midostaurin
How it works
Blocks the FLT3 tyrosine kinase enzyme, which is involved in signaling pathways that promote cancer cell growth and survival, preventing cancer cell proliferation.
Cancer types
Leukemia— FLT3-mutated
Efficacy
In clinical trials, around 50% of FLT3-mutated patients achieved a complete remission, with a median overall survival of approximately 25 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Gilteritinib and Midostaurin in Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Evaluating Midostaurin in Combination with Chemotherapy for Pediatric AML | Leukemia | phase-2 | — | Source → |
| Combining Midostaurin with CLAG-M Chemotherapy for AML | Leukemia | observational | The rate of complete remission (CR) plus CR with incomplete blood count recovery did not significantly differ between the 2 cohorts: CLAG-M, 86% versus 7+3, 70%. | Source → |
| New Study Examines Prognostic Scores for Advanced Mastocytosis Patients | Leukemia | observational | — | Source → |
| Midostaurin Reduces Relapse in Certain Leukemia Patients | Leukemia | phase-3 | The risk of death was reduced by 22% on the midostaurin-containing arm. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.